Serina Therapeutics, Inc. (SER)
Automate Your Wheel Strategy on SER
With Tiblio's Option Bot, you can configure your own wheel strategy including SER - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SER
- Rev/Share 0.0067
- Book/Share 0.1598
- PB 33.323
- Debt/Equity 0.1335
- CurrentRatio 2.4464
- ROIC -4.7008
- MktCap 57910478.0
- FreeCF/Share -2.0387
- PFCF -2.9115
- PE -60.3646
- Debt/Assets 0.0337
- DivYield 0
- ROE 0.1351
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics –
Read More
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, announced that it has made grants of options to purchase an aggregate of 15,000 shares of Serina's common stock to two new non-executive employees on March 20, 2025 (each, an “Option Grant”). Each Option Grant has an exercise price equal to the closing price of Serina's common stock on March 20, 2025. The Option Grants were offered as material inducement to the …
Read More
Serina Therapeutics to Present at JonesResearch Virtual CNS Day
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
HUNTSVILLE, AL, April 29, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT.
Read More
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
HUNTSVILLE, AL, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development Officer, will present new data at the ACS Spring 2025 Meeting and Expo in San Diego, CA. His presentation, titled "A Non-Immunogenic LNP for Gene Delivery: Characterization of Poly(oxazoline) Lipid Nanoparticles," will highlight findings on the immunogenic profile of Serina's proprietary POZ-lipid technology.
Read More
About Serina Therapeutics, Inc. (SER)
- IPO Date 2000-01-21
- Website https://serinatherapeutics.com
- Industry Biotechnology
- CEO Mr. Steven A. Ledger
- Employees 12